August 25, 2005
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and iCo Therapeutics Inc. announced today that Isis has granted an exclusive worldwide license to iCo for the development and commercialization of ISIS 13650, a second-generation antisense drug.
About iCo Therapeutics, Inc.
iCo Therapeutics Inc. is an emerging, Vancouver-based biotechnology company focused on developing pre-existing drugs for a range of new conditions affecting isolated biological environments – areas such as the eye, spinal cord, or joints – where locally-administered application of these therapies would have minimal systemic distribution and fewer safety issues.
For more information, visit the company website at: https://icotherapeutics.com.
Business Development Contact:
Dr. John Clement, CTO
Mr. John Meekison, CFO